Stock Track | Intellia Therapeutics Soars 5.07% Intraday on Strong Q4 Earnings Beat and Positive Pipeline Updates

Stock Track

Feb 27

Intellia Therapeutics' stock soared 5.07% during intraday trading on Thursday, following the release of its fourth quarter and full-year 2025 financial results.

The biotech company reported a significant earnings and revenue beat for the quarter. Intellia posted a loss of $0.83 per share, which surpassed analyst expectations. Quarterly sales of $23.017 million also dramatically exceeded estimates, representing a substantial year-over-year increase. Beyond the financial performance, the company provided encouraging updates on its clinical pipeline, including anticipated Phase 3 data for its lonvo-z treatment and the recent lifting of an FDA clinical hold on another key trial.

The positive results and pipeline progress have bolstered investor confidence, with the company noting a strong cash position expected to fund operations into the second half of 2027. Analyst commentary following the report has also been generally positive, contributing to the stock's upward movement during the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1101824655"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101824655\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101824655?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 03:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101824655","market":"nz","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Soars 5.07% Intraday on Strong Q4 Earnings Beat and Positive Pipeline Updates","media":"Stock Track","content":"<p>Intellia Therapeutics' stock soared 5.07% during intraday trading on Thursday, following the release of its fourth quarter and full-year 2025 financial results.</p><p>The biotech company reported a significant earnings and revenue beat for the quarter. Intellia posted a loss of $0.83 per share, which surpassed analyst expectations. Quarterly sales of $23.017 million also dramatically exceeded estimates, representing a substantial year-over-year increase. Beyond the financial performance, the company provided encouraging updates on its clinical pipeline, including anticipated Phase 3 data for its lonvo-z treatment and the recent lifting of an FDA clinical hold on another key trial.</p><p>The positive results and pipeline progress have bolstered investor confidence, with the company noting a strong cash position expected to fund operations into the second half of 2027. Analyst commentary following the report has also been generally positive, contributing to the stock's upward movement during the trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Soars 5.07% Intraday on Strong Q4 Earnings Beat and Positive Pipeline Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Soars 5.07% Intraday on Strong Q4 Earnings Beat and Positive Pipeline Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-27 03:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Intellia Therapeutics' stock soared 5.07% during intraday trading on Thursday, following the release of its fourth quarter and full-year 2025 financial results.</p><p>The biotech company reported a significant earnings and revenue beat for the quarter. Intellia posted a loss of $0.83 per share, which surpassed analyst expectations. Quarterly sales of $23.017 million also dramatically exceeded estimates, representing a substantial year-over-year increase. Beyond the financial performance, the company provided encouraging updates on its clinical pipeline, including anticipated Phase 3 data for its lonvo-z treatment and the recent lifting of an FDA clinical hold on another key trial.</p><p>The positive results and pipeline progress have bolstered investor confidence, with the company noting a strong cash position expected to fund operations into the second half of 2027. Analyst commentary following the report has also been generally positive, contributing to the stock's upward movement during the trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1101824655","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101824655","pubTimestamp":1772133318,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Intellia Therapeutics' stock soared 5.07% during intraday trading on Thursday, following the release of its fourth quarter and full-year 2025 financial results.The biotech company reported a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"股票追踪|Intellia Therapeutics盘中飙升5.07%，因第四季度盈利强劲增长和积极的管道更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Intellia Therapeutics' stock soared 5.07% during intraday trading on Thursday, following the release of its fourth quarter and full-year 2025 financial results.The biotech company reported a significant earnings and revenue beat for the quarter. Intellia posted a loss of $0.83 per share, which surpassed analyst expectations. Quarterly sales of $23.017 million also dramatically exceeded estimates, representing a substantial year-over-year increase. Beyond the financial performance, the company provided encouraging updates on its clinical pipeline, including anticipated Phase 3 data for its lonvo-z treatment and the recent lifting of an FDA clinical hold on another key trial.The positive results and pipeline progress have bolstered investor confidence, with the company noting a strong cash position expected to fund operations into the second half of 2027. Analyst commentary following the report has also been generally positive, contributing to the stock's upward movement during the trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}